Senores Pharma posts record Q2 revenue and ninth straight quarter of double-digit growth
Senores Pharmaceuticals reported record quarterly revenue and EBITDA in Q2 FY27, with revenue up 24.9% year on year, according to Moody's.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Indian drugmaker Senores Pharmaceuticals reported its highest-ever quarterly revenue and EBITDA for the second quarter of FY27, according to Moody's. Revenue for the quarter ended 30 September 2026 rose 24.9% year on year to Rs 192.3 crore. EBITDA climbed 38% to Rs 58 crore, and profit after tax grew 22% to Rs 37 crore. The EBITDA margin widened by about 290 basis points.
For the first half of FY27, revenue increased 30%, EBITDA rose 58% and profit after tax grew 31%. The regulated markets segment remained the main growth driver, generating Q2 revenue of Rs 136.7 crore. The company's ANDA portfolio grew from 34 to 64 products, and it expects revenue growth of 30–40% and PAT growth of 50–60% in FY27.
why it matters
The results show steady growth at a small pharmaceutical issuer, so the report matters mainly to its own investors. Management says scale-up from FY28 could improve operating leverage and margins, while setup costs at new facilities weighed on profitability in the quarter.
tags
instruments
sources
- Senores Pharma Logs Record Q2, Marks Ninth Quarter Of Double-Digit Growth — Moody's, 1 November 2026 at 02:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗